Anita Puranik

Anita Puranik

Auto-generated profile, based on publicly available information

Anita Puranik


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in bioRxiv
Verified
Preprint
Open access
Amanda Hanna SeekingsAmanda Hanna Seekings
Amanda Hanna Seekings
EBElizabeth Billington
Elizabeth Billington
SMSahar Mahmood
Sahar Mahmood
STSaumya S Thomas
Saumya S Thomas
APAnita Puranik
Anita Puranik
MSMarek Jozef Slomka
Marek Jozef Slomka
H7N7 low-pathogenicity avian influenza virus (H7N7-LPAIV) incursions have preceded emergence of H7N7 high-pathogenicity (HP)AIV at several European layer hen outbreaks. Evidence from a UK layer H7N7-HPAIV (2008) outbreak informed in vivo modelling of sequential events, beginning with H7N7-LPAIV precursor incursion. Three groups of 17-week-old (point-of-lay) hens were inoculated with three precursor H7N7-LPAIV candidates which possessed: Group 1 – the classic LPAIV single-basic cleavage site (CS) (H7N7-SBCS); Group 2 - the dibasic CS (H7N7-DBCS) discovered at the outbreak (both represented direct H7N7-HPAIV (2008) precursors); Group 3 - a related European H7N7-LPAIV (2008) which possessed a DBCS within its haemagglutinin (HA) gene which was highly-conserved with the HA of the UK (2008) outbreak H7N7-HPAIV, but its other genetic segments differed. In Groups 1-3, initial H7N7-LPAIV exposure caused limited viral shedding, restricted H7-antibody responses and no deaths, by 14-days post-inoculation (dpi). H7N7-HPAIV challenge of all groups (n=8 per challenge group, including AIV-naïve hens in Group 4) followed at 14 dpi. Prior H7N7-LPAIV inoculation protected against mortality due to H7N7-HPAIV challenge to varying degrees, with eight (100%), seven (87.5%), six (75%) and three (37.5%) survivors in Groups 1-4, respectively, by study-end (14-days post-challenge), when all 24 survivors had strongly seroconverted. Among challenge survivors belonging to Groups 1-3, 20/21 (95%) shed H7N7-HP, indicating that immunity acquired during initial H7N7-LPAIV exposure did not arrest H7N7-HPAIV replication. Despite prior H7N7-LPAIV incursion which elicited additional clinical protection against H7N7-HPAIV challenge, we showed how an emergent H7N7-HPAIV may represent a source for onward spread and further HPAIV outbreaks.